Myeloperoxidase (MPO) and eosinophil peroxidase (EPO) enzymes work
to preferentially kill a broad range of pathogens through a unique
mechanism of action unlikely to induce resistance. more
>>
Exoxemis, Inc. develops
haloperoxidase-based products for use in high value product areas
including medical, biodefense, industrial, disinfectant, and agricultural
applications. We are committed to integrating our technology with
the intellectual, financial, and commercial strengths of prospective
partners to develop innovative products and long-term relationships.
Effective January 1, 2008, Medicare will no longer reimburse inpatient acute care hospitals for the costs of treating “certain conditions that could reasonably have been prevented”.
Find out more >>
